A Phase 2 Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer Who Have Received Two or Three Prior Systemic Chemotherapy Regimens
NCT #
NCT05513742
Condition(s)
Colorectal Cancer
Molecular Target(s)
DLL4, VEGF-A
Drug Classification(s)
Bispecific Monoclonal Antibody
Agents(s)
CTX-009
Phase(s)
II
Mechanism of Action
CTX-009 simultaneously targets, binds to and blocks DLL4 and VEGF-A. This prevents the activation of DLL4/Notch- and VEGF-A/VEGF receptor (VEGFR)-mediated signaling pathways, which play key roles in angiogenesis and tumor vascularization. This prevents angiogenesis and may halt tumor cell prolifration.
Purpose
- The effects of the study drug (good and bad)
- How the study drug is acting on your body
- How much of the study drug is absorbed into the blood and how fast it is removed
Location
MCD
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.